Highlights Vicore Pharma Holding AB

Equities

VICO

SE0007577895

Market Closed - Nasdaq Stockholm Other stock markets 11:59:34 08/05/2024 BST			5-day change	1st Jan Change
19.9 ^SEK	-0.75%		+10.19%	+40.34%

05-07	Vicore Pharma Holding AB Announces Board Appointments	CI
05-03	Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis	03-19	CI
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	02-09	MT
Alex Therapeutics and Vicore Pharma Announces Positive Results of the COMPANION Study	01-04	CI
Vicore Pharma Holding AB Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates	01-02	CI
Vicore Pharma Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Vicore Pharma Holding AB Provides Update Regarding Phase 1 Study of C106	27/10/23	CI
Vicore Pharma Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Vicore Pharma Holding AB Reports Data from EndoPAT® Exploratory Trial	22/08/23	CI
EU Grants Patent to Vicore Pharma's Improved Pulmonary Fibrosis Drug Candidate	07/06/23	MT
Vicore Pharma Holding AB Reports New 36-Week Data from the Air Trial Demonstrating Sustainable Disease Stimulating the Potential of A New Class of Drugs to Stop Disease Propose and Restate in IPF Patients	19/05/23	CI
Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
Vicore Pharma Holding AB Initiates Clinical Proof-Of-Concept Study of Endothelial Dysfunction	03/05/23	CI
Vicore Pharma Holding AB Receives Innovation Passport Designation by the UK Regulatory Agency MHRA for C21 in IPF	29/03/23	CI
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	28/02/23	CI
Vicore Pharma Holding AB Announces First Patient Enrolled in COMPANION; a Digital Therapeutic Pivotal Study for Patients with Pulmonary Fibrosis	05/12/22	CI
Vicore Pharma Holding AB Announces New Data from the IPF Air Trial Further Strengthening the Benefit-Risk Profile of C21	03/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vicore Pharma Holding AB

Equities

VICO

SE0007577895

Highlights

Filters